1 oncology trials approved in Europe
1 oncology trials approved in Europe
A concise selection of oncology and haematology clinical trials added or updated since the previous edition.
Oncology Hero Trial Feed connects oncology professionals with relevant clinical trials.
A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
| Sponsor: Janssen Cilag International | Phase: 3 |
| Disease: Metastatic castration-resistant prostate cancer (mCRPC) | EU trial number: 2023-508606-26-00 |
Interested in offering this trial to suitable patients?
Register Investigator InterestFor qualified healthcare and research professionals. Registration expresses investigator interest; it is not patient enrollment.
Oncology Hero
Sharing the latest updates in oncology
In partnership with Oncology Updates — Aug 26 to Sep 2025 September delivered practice-relevant oncology updates worldwide — guideline shifts, pivotal trial readouts, new approvals, and high-impact AI tools. Below is a concise, clinician-first roundup. 🎗️ 🩺Lung cancer ESMO issues NSCLC guideline for early & locally advanced disease New recommendations standardize biomarker-driven multimodality care in stage I–III NSCLC, including integration of IO/targeted therapy in pathways. Read more...
Oncology Updates — August 2025 August 2025 delivered practice-relevant oncology updates worldwide — fresh guideline shifts, pivotal trial readouts, new approvals, diagnostics/devices, and high-impact AI tools. Below is a concise, clinician-first roundup, capped with a focused deep dive on the updated ASCO NSCLC guidelines. 🎗️ 💼 Earn for training the next generation of AI tools Medical Expert Hourly contract · Remote · $130–$180 per hour Apply here Physicians, Pathologists (Health Care and...
Regeneron Acquires 23andMe Research Division for $256M in Bankruptcy Auction Context: As 23andMe navigates Chapter 11 proceedings, key assets tied to its vast genomic database and pharma partnerships have drawn industry attention. What's New? Regeneron has secured a $256 million deal to acquire 23andMe’s therapeutics subsidiary, aiming to leverage the platform’s extensive genotypic and phenotypic data to fuel its precision medicine pipeline. Why it Matters? This acquisition gives Regeneron a...